ABSTRACT A murine monoclonal antibody, 13.1, which blocks human natural killer (NK) cell-mediated lysis, has been developed. Hybridoma 13.1 was derived by fusion of NS-1 cells with spleen cells from mice immunized with an enriched population of NK cells. Supernatants of growing hybridomas were screened for their ability to block NK cell-mediated lysis of K562 targets. Antibody 13.1 is an IgG1 with a single light chain type and it does not fix complement. The 13.1 antigen is expressed on all peripheral blood mononuclear cells, with an antigen density approximately 1/30th that of HLA antigen heavy chain. Pretreatment and washing experiments revealed that inhibition of cytotoxicity occurred at the effector cell level only. Significant blocking was achieved with nanogram quantities of antibody and was not due to toxic effects on NK cells. Likewise, controls with other antibodies of the same subclass demonstrated that blocking was not a consequence of mere binding to NK cells. When a panel of 17 NK cell-susceptible targets was tested, the lysis of only 5 of these was blocked, namely K562, HL-60, KG-1, Daudi, and HEL, a human erythroleukemic cell line. The lysis of 12 human B cell and T cell line targets was not inhibited. In addition to the demonstration that the 13.1 antigen is a crucial cell surface structure involved in NK lysis, a heterogeneity of target cell recognition has been revealed that argues for the proposition that individual NK cells have multiple recognitive capabilities.
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Persuasive evidence culled from in vivo experiments demonstrates a role for natural killer (NK) cells in resisting the growth of tumors (1) (2) (3) . Additional experiments with targets derived from a variety of embryonic or undifferentiated normal tissues suggests NK cells may also regulate host cell differentiation (4) (5) (6) . Though not all cells are lysed by NK cells, the wide variety of tumor targets-tumors of lymphoid, myeloid, erythroid, embryonal, and fibroblast lineages, as well as xenogeneic tumors-raises the issue of whether there is any specificity to the binding and lytic phases. Unlabeled target inhibition and monolayer absorption experiments are consistent with a multiplicity of NK target structures (7) (8) (9) . However, Collins et al. have suggested that the susceptibility of fibroblasts to NK cell lysis may be determined primarily by the lack of an adequate target repair mechanism (2). A major unresolved issue, therefore, is the nature of the NK cell recognition process.
The use ofantibodies, in the absence ofcomplement, to block murine cytotoxic T cell function at either the effector (10) (11) (12) or target (13) cell level has provided information on both candidate T cell receptors and target cell fine structures. This approach has not yet been fully exploited for the examination of NK cell recognition or target structures.
An earlier report from this laboratory described the use of antibody 9.6, directed to the human T cell sheep erythrocyte (E) receptor (14) , to block NK cell function (15 51Cr Release Assay. NK and antibody-dependent cell-mediated cytotoxicity (ADCC) assays were performed as described (15) . Briefly, effector PBL (105) were placed in V-bottom microtiter wells with 51Cr-labeled target cells (usually 103). Plates were spun gently and incubated at 370C for 4 hr. One half of the supernatant (100 ,ul) was harvested and its radioactivity was measured in a gamma counter. Results are expressed as % specific lysis based upon the formula [(experimental -spontaneous)/(freeze thaw -spontaneous)] X 100.
For screening ofhybridoma supernatants, effector cells were obtained by thawing aliquots from a large pool of PBL obtained for this purpose by leukopheresis and frozen in 10% dimethyl sulfoxide under liquid N2. To optimize NK activity, PBL were first cultured overnight in RPMI 1640 medium/10% pooled human serum from nontransfused males; the medium contained poly(I.C) (Sigma) at 50 .ug/ml for induction of interferon (IFN). 
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The publication costs ofthis article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 Antibody Purification. BALB/c mice were primed by intraperitoneal injection of 1.0 ml of pristane (Aldrich) 6-10 days prior to intraperitoneal injection of 2 x 107 cloned hybridoma cells. Ten to 14 days later, ascites fluids were collected, spun to remove cells, and sterilized by filtration. Antibody 13.1 was purified in a single step by absorption and elution from staphylococcal protein A coupled to Sepharose (Sigma). Ascites fluid was applied to a column of protein A-Sepharose in 0. Fig. 1 shows results from a portion of the screening of fusion 13 . Controls show that HAT medium had no effect on the NK assay compared to normal medium. In addition, antibody 9.6 as a positive control exhibited approximately 50% blocking, and MOPC-21 had no effect at 0.1 mg/ ml. As can be seen from the results obtained in column 6, well E6 exhibited significant reduction in the amount of 51Cr released from K562 target cells. Hybridoma cells from well E6 have been cloned seven times by limiting dilution on a feeder layer of thymocytes.
Characterization of Antibody 13. (MOPC-21) . Specific inhibition is detected in culture supernatants of clone 9.6 at 5 ,ug/ml. Below are the results from one row of fusion 13, demonstrating inhibition of 51Cr release by the supernatant of well E6. be eluted from protein A-Sepharose at pH 5.5 (21) . The antibody was further analyzed by two-dimensional gels. As shown in Fig. 2, 13 .1 possesses single heavy and light chains.
Expression of 13.1 Antigen on PBL. Fig. 3 shows the relative fluorescence intensities of staining of PBL with 13.1 compared to two other monoclonal antibodies: 9.6, an anti-E receptor, and 34/28 (19) , an IgGl antibody specific for HLA. All antibodies were tested at saturating concentrations. As can be seen, all PBL stained with 13.1 with a weak fluorescence intensity. Antibody 34/28 stained with approximately a 30-fold greater intensity than 13.1 and antibody 9.6 stained with approximately a 6-fold greater intensity than 13.1. Direct examination of 13.1-stained PBL in the fluorescence microscope revealed that less than one in 500 cells lacked 13.1 antigen expression.
Effect ofAntibody 13.1 on NK Cell-Mediated Lysis. Purified antibody 13.1 was tested for ability to block lysis of K562 targets at a range of antibody concentrations. As shown in Fig. 4 Table 2 for each cell line are representative experiments. Each target was tested with at least five different donors.
Effector cells were blocked in their lysis of the erythroleukemia target cells K562 and HEL, the myelocytic leukemia cells KG-1, and the promyelocytic leukemia cells (Table 2A) . No blocking of lysis of six different T lymphoma cell lines was observed, nor was there any effect on ADCC with antibodycoated Chang liver cell targets. Table 2B presents results from the NK cell-mediated lysis of B cell line targets. In order to achieve sufficient lysis, the effector cells were preincubated for 18 Table  2 were reproducible over a range of antibody concentrations InA, 2 x 105 effector cells were treated with antibody 13.1 at 10,ug/ ml in microtiter plates, followed by addition of 2 x 103 51Cr-labeled targets. ALL, acute lymphocytic leukemia. In B, effector cells were incubated overnight in RPMI 1640 medium/10% pooled human serum containing poly(I-C) at 50 ,ug/ml to augment NK lysis. Cells were washed twice prior to assay and preincubated for 30 min with antibody 13.1 at 10 yg/ml, followed by addition of 51Cr-labeled targets. Ratio of unlabeled to labeled targets FIG. 5 . Effector PBL were incubated in the presence of MPOC-21 at 10 pzg/ml (o) or 13.1 at 10 ,g/ml (.) for 1/2 hr at 22°C. Thereafter unlabeled Jurkat (Left) or K562 (Right) targets were added to all wells at various doses, followed by addition of 2 x 103 51Cr-labeled Jurkat targets. Lysis in the absence of competitors was 25%. between 1 ug/ml and 1 ng/ml and at effector-to-target ratios of 50:1 and 25:1 (data not shown).
Analysis. (19) . Antibody 34/28 failed to block NK cell lysis despite the fact that 30-fold more 34/28 than 13.1 antibody binds to PBL. In a previous publication it was also shown that two other monoclonal reagents, W6/32 anti-HLA of the IgG2a subclass (16) and OKM1 (22) , both ofwhich bind to NK cells, do not block NK cell lysis in the absence of complement. Abo and Balch (23) have described a monoclonal antibody specific for human NK and ADCC cells, HNK-1, which in the absence of complement does not block NK cell lysis. Hence, antibody binding to NK cells is insufficient to block lysis. Moreover, blocking is not due to toxic effects on NK cells, because cytolytic activity is recoverable and antibody 13.1 does not block lysis of cytotoxic T lymphocytes (CTL) (unpublished results). Pretreatment of effector or target cells with antibody 13.1, followed by washing, revealed that blocking was achieved at the effector cell level.
Medical Sciences: Newman e I 'Of special interest is the observation that antibody 13.1 is selective in its inhibitory ability. Only 5 of 17 targets tested were inhibited from lysis when a 1,000-fold excess of the amount of antibody required to achieve 50% inhibition of K562 lysis was used. Likewise, no inhibition ofADCC against Chang cells was observed.' Those targets whose lysis was blocked were primarily of the myeloid and erythroid lineages. The one exception was 'the Daudi cell line. Lysis of other B cell targets, including two Burkitt lymphoma-derived B lines, was unaffected, as was the lysis of six different T cell lines derived from leukemia patients. Further studies will be necessary to ascertain whether there are any cell surface molecules uniquely expressed (or lacking) on those cell lines whose lysis is inhibited.
To analyze the mechanism by which lysis is blocked, advantage was taken of two observations: first, that K562 cells effectively compete with 51Cr-labeled Jurkat targets for NK cells; and, second, that antibody 13. 1 blocks lysis of K562 and does not block lysis of Jurkat targets. Hence, it was feasible to ask whether NK Iysis of Jurkat cells was inhibited as well by K562 in the presence as in the absence of antibody 13.1. Whereas K562 targets were rendered inefficient competitors by pretreatment of NK cells with antibody 13.1, no effect-on the competitive ability ofJurkat cells was observed. Moreover, the ability of K562 to compete with Jurkat cells for NK cells in the absence of antibody 13.1 indicates that these targets.compete for the same pool of effector NK cells.
This set of observations is best explained by postulating that NK cells possess multiple recognition structures. If lysis of these two targets was achieved by distinct NK cells with different receptors, then K562 would not be an efficient competitor of the lysis of Jurkat cells. Furthermore, it seems unlikely that NK cells recognize K562 and Jurkat targets via a common structure, given the selective inhibitory effects ofantibody 13.1.
A model of multivalent NK cells is consistent with.the observation that many different kinds of unlabeled targets can compete with a single 51Cr-labeled target (7, 24) and that NK specificity does not segregate upon cloning (25) . The multivalent model does not require that all NK cells possess the same set of receptors; subsets of NK cells may'differ in the distribution ofreceptor expression. This.might explain the occasional ability to adsorb NK effectors on monolayers of targets in a specific manner (26) . However, validation of the multireceptor hypothesis will have to await experiments with cloned human NK cells.
The 13.1 antigen is similar to the murine Ly-5 antigen in its expression on all lymphoid cells and in its ability to block NK cell but not'CTL-mediated lysis (27) . A murine antigen, H-ll, which is distinct from Ly-5, has recently been described; antibody binding to this determinant also selectively blocks NK and not CTL activity (28) . We have previously demonstrated that antibody 9.6 anti-E receptor (14) blocks human NK as well as CTL-mediated lysis (15 
